Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.97 |
| ▸ | HTR2C | P28335 | 5/20 | 0.97 |
| ▸ | TSHR | P16473 | 4/20 | 0.97 |
| ▸ | BLM | P54132 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 4/20 | 0.97 |
| ▸ | HTR1A | P08908 | 4/20 | 0.97 |
| ▸ | HTR2A | P28223 | 4/20 | 0.97 |
| ▸ | HTR2B | P41595 | 4/20 | 0.97 |
| ▸ | MAPT | P10636 | 4/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | HTR7 | P34969 | 2/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.97 |
| ▸ | MTOR | P42345 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxitriptan SCHEMBL4452810 | 1.00 | NPSR1 (0.97) | NPSR1HTR2CTSHRBLMLMNA | |
| Oxitriptan SCHEMBL4452809 | 1.00 | NPSR1 (0.97) | NPSR1HTR2CTSHRBLMLMNA | |
| Oxitriptan SCHEMBL990124 | 1.00 | NPSR1 (0.97) | NPSR1HTR2CTSHRBLMLMNA | |
| Oxitriptan SCHEMBL3033706 | 0.99 | NPSR1 (1.00) | NPSR1HTR2CTSHRBLMLMNA | |
| Oxitriptan SCHEMBL1421238 | 0.99 | NPSR1 (1.00) | NPSR1HTR2CTSHRBLMLMNA | |
| Oxitriptan SCHEMBL19871232 | 0.99 | NPSR1 (1.00) | NPSR1HTR2CTSHRBLMLMNA | |
| Oxitriptan SCHEMBL29498813 | 0.99 | NPSR1 (1.00) | NPSR1HTR2CTSHRBLMLMNA | |
| Oxitriptan SCHEMBL21114382 | 0.99 | NPSR1 (1.00) | NPSR1HTR2CTSHRBLMLMNA | |
| Oxitriptan SCHEMBL21114383 | 0.99 | NPSR1 (1.00) | NPSR1HTR2CTSHRBLMLMNA | |
| Oxitriptan SCHEMBL43242 | 0.99 | NPSR1 (1.00) | NPSR1HTR2CTSHRBLMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069206-B1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | ALESCO SRL (IT) | 2024-08-07 | — | — | EP | claimed |
| US-20230013586-A1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | PHARMANUTRA S.P.A. (IT) | 2023-01-19 | — | — | US | claimed |
| EP-4070801-A1 | COMPOSITIONS OF INSULIN AND CHROMIUM FOR THE TREATMENT AND PREVENTION OF DIABETES, HYPOGLYCEMIA AND RELATED DISORDERS | Nutrition 21, LLC (US) | 2022-10-12 | — | — | EP | claimed |
| EP-4069206-A1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | Alesco S.r.l. (IT) | 2022-10-12 | — | — | EP | claimed |
| WO-2021111407-A1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | ALESCO S.R.L. (IT) | 2021-06-10 | — | — | WO | claimed |
| EP-3513790-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | JDS Therapeutics, LLC (US) | 2019-07-24 | — | — | EP | claimed |
| EP-2448412-B1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | JDS THERAPEUTICS LLC (US) | 2019-05-01 | — | — | EP | claimed |
| US-20150224140-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2015-08-13 | — | — | US | claimed |
| EP-2012770-A2 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Interhealth Nutraceuticals, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007121312-A9 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS INC (US) | 2008-07-17 | — | — | WO | claimed |
| WO-2007121312-A2 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | claimed |
| US-20250275982-A1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | ALESCO S.R.L. (IT) | 2025-09-04 | — | — | US | disclosed |
| EP-4069206-B1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | ALESCO SRL (IT) | 2024-08-07 | — | — | EP | disclosed |
| EP-4282281-A2 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | Alesco S.r.l. (IT) | 2023-11-29 | — | — | EP | disclosed |
| US-20230013586-A1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | PHARMANUTRA S.P.A. (IT) | 2023-01-19 | — | — | US | disclosed |
| WO-2011002939-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | NUTRITION 21, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20090092560-A1 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| EP-2012770-A2 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Interhealth Nutraceuticals, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121312-A9 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS INC (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2007121312-A2 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224140-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | SLC2A3, SLC2A1, SLC2A2 | NPSR1 1729/4885HTR2C 1176/4885TSHR 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.